Entering text into the input field will update the search result below

Selecta Biosciences GAAP EPS of $0.08 beats by $0.19, revenue of $34M beats by $20.88M

May 05, 2022 7:41 AM ETCartesian Therapeutics, Inc. (RNAC)By: Anuron Mitra, SA News Editor
  • Selecta Biosciences press release (NASDAQ:SELB): Q1 GAAP EPS of $0.08 beats by $0.19.
  • Revenue of $34M (+207.7% Y/Y) beats by $20.88M.
  • SELB had $118.8 million in cash, cash equivalents, marketable securities, and restricted cash as of March 31, 2022, as compared to cash, cash equivalents, marketable securities, and restricted cash of $129.4 million as of December 31, 2021.

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About RNAC

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Cartesian Therapeutics, Inc.
PDS Biotechnology Corporation
Foghorn Therapeutics Inc.
Stoke Therapeutics, Inc.
Mersana Therapeutics, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.